•Iron overload may increase glaucoma risk•VIEW Optometry launches to support independent practices•4DMT completes enrollment for phase 3 wet AMD gene therapy trial•Seasonal variations play major role in CSC development•BVI reports first US implantations of FINEVISION HP Trifocal IOL•Iron overload may increase glaucoma risk•VIEW Optometry launches to support independent practices•4DMT completes enrollment for phase 3 wet AMD gene therapy trial•Seasonal variations play major role in CSC development•BVI reports first US implantations of FINEVISION HP Trifocal IOL
HEADLINES
FEATURED
Settlement and license agreement clears the way for a January 2027 commercial launch of OPUVIZ 2 mg (aflibercept-yszy) injection.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
